News

Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism, and its role in chronic inducible urticaria.

Michael Wechsler, MD, reports 59% of patients in clinical remission with twice-yearly depemokimab at year 1 maintained it at year 2 in SWIFT/AGILE.

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.

AAD and HSF issued the first joint hidradenitis suppurativa guidelines, outlining 37 recommendations and flagging step therapy as a major barrier.

A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.

Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.

A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.

Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.

From false positives to lost follow-up and unneeded LTBI therapy, experts detail the harms of routine TB testing with IL-17 and IL-23 inhibitors in psoriasis.

The NPF/IPC TB statement isn’t a blanket no-test rule. Experts explain when screening still fits, from endemic regions to JAK inhibitors and other DMARDs.

Experts explain why ustekinumab and TYK2 inhibitors were excluded from new TB testing guidance and how FDA label changes for IL-17/IL-23 agents could happen.

Basic science, trials, real-world data, and FAERS reports show little TB reactivation risk with IL-17 and IL-23 inhibitors, supporting new NPF/IPC guidance.

New NPF/IPC guidance questions routine TB testing for IL-17 and IL-23 inhibitors in psoriasis, a TNF-era practice lacking direct supporting evidence.

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.

Todd Schlesinger, MD, discusses Ameluz PDT for sBCC, adjuvant cemiplimab, remibrutinib for symptomatic dermographism, and nonsurgical skin cancer care.

In an interim extension analysis presented at NACFC 2026, 37.5% of young children with CF in a PERT substudy stopped enzyme therapy on the regimen.

Day 2 highlights from Phoenix covering PE intervention trials, pulmonary hypertension diagnostics, ILD telomere biology, and more.

Samantha Pettigrew, MD, reviews HI-PEITHO, PRAGUE-26, and PEERLESS and how they shape intervention choices in intermediate-risk PE at CHEST 2026.

Anjali Vaidya, MD, explains why echocardiography should inform right heart catheterization interpretation in pulmonary hypertension at CHEST 2026.

In 503 patients with ILD, telomere length below the 10th percentile was linked to UIP pattern on CT and higher MIL-UIP scores but not greater fibrosis extent.

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.